- Bookmark
- Share
- CaseIQ
Merck Sharp & Dohme Corp v Clonmel Healthcare Ltd
Factual and Procedural Background
Company A (“Plaintiff/Appellant”) holds European Patent 0 720 599 covering the active ingredient ezetimibe and obtained Supplementary Protection Certificate 2005/2001 (“the 001 SPC”) for a combination drug marketed as Inegy. The 001 SPC was due to expire on 1 April 2019. Company B (“Defendant/Respondent”), a generic manufacturer, launched a competing product on 17 April 2018, the day after an earlier SPC on ezetimibe had lapsed. Company A obtained an interim ex parte injunction, but the High Court refused an interlocutory injunction. A majority of the Court of Appeal upheld that refusal; one judge dissented. The Supreme Court heard Company A’s further appeal after the 001 SPC itself had expired, on the agreed basis that the appeal should nonetheless be decided on the facts as they stood in April 2018.
Legal Issues Presented
- What is the correct test for granting an interlocutory injunction where the intellectual-property right (here, an SPC) is close to expiry?
- How should courts weigh the adequacy of damages versus irreparable harm when a patentee seeks to restrain a generic “at-risk” launch?
- Does the existence of a presumptively valid SPC tilt the balance of convenience in favour of the patentee, or does the potential “first-mover” advantage of a generic entrant tilt it the other way?
Arguments of the Parties
Plaintiff/Appellant’s Arguments
- Cited extensive UK authority indicating that generic entry typically causes an irreversible, unquantifiable price collapse that damages the patentee beyond monetary compensation.
- Asserted that Company B had failed to “clear the path” (i.e., seek revocation or a declaration of non-infringement) before launching, a factor UK courts treat as favouring injunctive relief.
- Contended that the 001 SPC is presumptively valid and represents more than a mere “income stream”; it confers an exclusive right that should be protected.
Defendant/Respondent’s Arguments
- Relied on Irish authority, especially Curust Financial Services Ltd v Loewe-Lack-Werk, to argue that Company A’s loss would be a “purely commercial” one in a stable market and therefore adequately compensable in damages.
- Maintained that, if restrained but ultimately successful, Company B would lose an unquantifiable “first-mover” advantage as the incumbent generic—harm that damages could not adequately remedy.
- Challenged the factual basis for the Plaintiff’s “downward price spiral” argument and characterised it as speculative.
Table of Precedents Cited
| Precedent | Rule or Principle Cited For | Application by the Court |
|---|---|---|
| American Cyanamid Co v Ethicon Ltd [1975] AC 396 | Foundational test for interlocutory injunctions (serious question; balance of convenience; adequacy of damages). | Central framework; Court analysed whether Irish practice had become overly rigid and re-emphasised flexibility. |
| Campus Oil v Minister for Industry (No. 2) [1983] IR 88 | Adopts American Cyanamid in Ireland. | Used to assess whether damages are adequate and to balance convenience. |
| Curust Financial Services Ltd v Loewe-Lack-Werk [1994] 1 IR 450 | Where loss is purely commercial in a stable market, damages are generally adequate. | Majority below relied heavily on this case; Supreme Court held it should not be treated as an inflexible rule. |
| SmithKline Beecham plc v Apotex Europe Ltd [2003] EWCA Civ 137 | Generic entry can cause irreversible price erosion justifying interim relief. | Illustrated UK approach favouring injunctions in pharmaceutical patent/SPC disputes. |
| Novartis AG v Hospira UK Ltd [2013] EWCA Civ 583 | Emphasises need for generics to “clear the path” before launch. | Cited as persuasive authority supporting injunction where generic had not litigated validity pre-launch. |
| Warner-Lambert Co v Teva UK Ltd [2011] EWHC 1691 | Risk of unquantifiable loss to patentee from early generic entry. | Part of UK line of authority the Plaintiff asked the Court to follow. |
| AstraZeneca AB v Teva UK Ltd [2017] CSOH 150 | Scottish decision confirming the same UK trend. | Reinforced Plaintiff’s submission that interim relief is the norm in such disputes. |
| NWL Ltd v Woods [1979] 1 WLR 1294 | Where no trial is likely, court may evaluate merits more closely. | Majority below invoked it; Supreme Court found the case distinguishable because a trial on damages was inevitable. |
| Okunade v Minister for Justice [2012] IESC 49 | Weight may be given to validity of administrative decisions pending challenge. | Analogy used to give presumptive weight to the granted SPC. |
Court's Reasoning and Analysis
Judge O’Donnell (for a unanimous Supreme Court) emphasised the flexible, equitable nature of interlocutory relief and cautioned against turning precedents into rigid rules. Key points:
- Re-appraisal of Curust. The decision does not create a blanket principle that damages are always adequate in commercial IP disputes; its famous dictum must be read in context.
- Adequacy of damages is relative, not absolute. Both parties would likely suffer some irreparable harm: Company A from uncontrolled generic penetration; Company B from loss of first-mover status if wrongly enjoined. Neither side’s loss was fully compensable in money.
- Presumption of validity. An SPC is granted through a statutory scheme and is valid until set aside. That status is a material factor favouring interim protection.
- Failure to “clear the path.” Company B did not commence validity proceedings in advance, unlike defendants in some earlier Irish cases. This counted against it in the balance.
- Symmetry of interests. The dispute centres on a single issue—validity of the 001 SPC—so the fairest course would have been to preserve the pre-launch status quo and order an expedited trial.
- Guidance for future cases. The Court set out an eight-step checklist, reaffirming that adequacy of damages is usually pivotal but other equitable factors (status quo, public interest, procedural posture) may tip the scales.
Holding and Implications
Holding: The appeal was allowed; the Supreme Court concluded that an interlocutory injunction should have been granted to Company A as of April 2018.
Implications: Although the underlying SPC has since expired, the judgment recalibrates Irish interlocutory-injunction doctrine in patent/SPC cases. It rejects a rigid “damages-are-enough” approach, affirms the relevance of an IP right’s presumptive validity, and signals that generics launching “at risk” without clearing the way face a higher hurdle. The decision provides an eight-step analytical framework expected to guide future commercial-equity applications, but stops short of creating an automatic rule in favour of patentees.
Alert